<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135486</url>
  </required_header>
  <id_info>
    <org_study_id>711202/001</org_study_id>
    <nct_id>NCT00135486</nct_id>
  </id_info>
  <brief_title>Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants</brief_title>
  <official_title>Evaluate Immunogenicity, Reactogenicity, Safety of GSK Biologicals' MenC-TT Vaccine (2 Formulations) Given With Infanrix Hexa® + GSK Biologicals' Hib MenC-TT Vaccine (2 Formulations) Given With Infanrix Penta® to Infants in Mths 3,4,5 of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this primary vaccination study is to evaluate the immunogenicity, safety and
      reactogenicity of three doses of GSK Biologicals' MenC-TT (Neisseria meningitidis group C
      polysaccharide-tetanus toxoid) vaccine (2 different formulations) and of three doses of GSK
      Biologicals' Hib-MenC-TT (Haemophilus influenzae type b-MenC-TT) vaccine (2 different
      formulations) when given to infants in their 3rd, 4th, and 5th months of life. Concomitant
      vaccines were given to all children to complete the vaccination agenda.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Five parallel treatment groups receiving a 3-dose primary vaccination course: MenC-TT vaccine
      (2 formulations, double-blind) + Infanrix hexa® OR Hib-MenC-TT (2 formulations double-blind)
      + Infanrix penta® OR Meningitec™ + Infanrix hexa® (control). Three blood samples taken,
      before dose 1 and one month after dose 2 and dose 3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Meningococcal C serum bactericidal assay using rabbit complement (rSBA-MenC) antibody titers ≥ 1:8 &amp; ≥ 1:128 and titers</measure>
    <time_frame>Prior to vaccination, one month after the 2nd and 3rd vaccine doses</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-polysaccharide C (anti-PSC) antibody concentrations ≥ 0.3 µg/mL &amp; ≥ 2 µg/mL and concentrations</measure>
    <time_frame>Prior to vaccination, one month after the 2nd and 3rd vaccine doses</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-polyribosyl ribitol phosphate (anti-PRP) antibody concentrations ≥ 0.15 µg/mL &amp; ≥ 1 µg/mL and concentrations</measure>
    <time_frame>Prior to vaccination, one month after the 2nd and 3rd vaccine doses</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-diphtheria antibody concentrations ≥ 0.1 IU/mL by ELISA</measure>
    <time_frame>Prior to and one month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-tetanus antibody concentrations ≥ 0.1 IU/mL</measure>
    <time_frame>Prior to and one month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-hepatitis B surface antigen (anti-HBs) antibody concentrations ≥ 10 mIU/mL</measure>
    <time_frame>Prior to and one month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-poliovirus types 1, 2 and 3 antibody titers ≥ 8 mIU/mL</measure>
    <time_frame>Prior to and one month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine response to pertussis toxoid (PT)</measure>
    <time_frame>Prior to 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-diphtheria antibody concentrations</measure>
    <time_frame>Prior to 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-poliovirus types 1, 2 and 3 antibody titers</measure>
    <time_frame>Prior to and one month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of solicited local injection site symptoms</measure>
    <time_frame>During the solicited follow-up period (Day 0 7) following administration of each vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of solicited systemic symptoms</measure>
    <time_frame>During the solicited follow-up period (Day 0 7) following administration of each vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of unsolicited non-serious adverse events (AEs)</measure>
    <time_frame>Within one month (Day 0 30) after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any serious adverse events (SAEs)</measure>
    <time_frame>Throughout the entire study period up to and including one month (maximum 30 days) after the last vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine response to pertussis toxoid (PT)</measure>
    <time_frame>One month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine response to filamentous haemagglutinin (FHA)</measure>
    <time_frame>Prior to 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine response to filamentous haemagglutinin (FHA)</measure>
    <time_frame>One month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine response to pertactin (PRN)</measure>
    <time_frame>Prior to 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine response to pertactin (PRN)</measure>
    <time_frame>One month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-diphtheria antibody concentrations</measure>
    <time_frame>One month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-tetanus antibody concentrations</measure>
    <time_frame>Prior to 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-tetanus antibody concentrations</measure>
    <time_frame>One month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-HBs antibody concentrations</measure>
    <time_frame>Prior to 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-HBs antibody concentrations</measure>
    <time_frame>One month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-PT antibody concentrations</measure>
    <time_frame>Prior to 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-PT antibody concentrations</measure>
    <time_frame>One month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-FHA antibody concentrations</measure>
    <time_frame>Prior to 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-FHA antibody concentrations</measure>
    <time_frame>One month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-PRN antibody concentrations</measure>
    <time_frame>Prior to 3rd vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of anti-PRN antibody concentrations</measure>
    <time_frame>One month after the 3rd vaccine dose</time_frame>
  </primary_outcome>
  <enrollment type="Actual">500</enrollment>
  <condition>Infections, Meningococcal</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenC-TT</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hib-MenC-TT</intervention_name>
    <other_name>MenC-TT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female infants, 8 to 16 weeks of age at the time of the first
             vaccination.

        Exclusion Criteria:

          -  Previous vaccination against OR history of OR exposure since birth to diphtheria,
             pertussis, tetanus, polio, hepatitis B, Hib and/or meningococcal disease.

          -  Planned administration/administration of a vaccine not foreseen in the study since
             birth.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of any neurologic disorders or seizures, allergic disease or reactions likely
             to be exacerbated by any component of the vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Weeks</minimum_age>
    <maximum_age>16 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilus Influenzae type b/Meningococcal vaccine</keyword>
  <keyword>Prophylaxis meningococcal serogroup C disease, Hib diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>711202/001</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>711202/001</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>711202/001</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>711202/001</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>711202/001</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>711202/001</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

